Table 2 Baseline characteristics according to the outcome at follow-up
Characteristic | n | Stable | Progressed | p value |
|---|---|---|---|---|
n = 345 | n = 84 | |||
Demographics | ||||
Female, n (%) | 429 | 191 (55) | 39 (46) | < .0001 |
Age, years | 429 | 65 ± 9 | 72 ± 8 | < .0001 |
Duration of symptoms, years | 380 | 3 ± 3 | 3 ± 3 | 0.36 |
MCI/AD/non-AD, n | – | 16/44/24 | NA | |
CDR, n (0.0/0.5/1.0) | 424 | 198/136/6 | 11/52/4 | NA |
APOE status | ||||
APOE e4 carrier, n (%) | 146 | 50 (14) | 14 (17) | 0.12 |
Cognitive tests | ||||
MMSE | 427 | 28 ± 2 | 26 ± 3 | < .0001 |
Memory—learning | 420 | 42 ± 11 | 31 ± 10 | < .0001 |
Memory—recall | 420 | 9 ± 4 | 4 ± 3 | < .0001 |
TMT-A, seconds | 422 | 42 ± 19 | 58 ± 30 | < .0001 |
TMT-B, seconds | 402 | 102 ± 60 | 164 ± 82 | < .0001 |
Fluency—animal | 407 | 23 ± 7 | 18 ± 6 | < .0001 |
Fluency—letter | 377 | 14 ± 5 | 12 ± 5 | 0.006 |
Clock-drawing | 394 | 3 ± 1 | 2 ± 1 | < .0001 |
CSF | ||||
Aβ42, pg/ml | 145 | 933 ± 285 | 748 ± 338 | 0.002 |
P-tau, pg/ml | 145 | 53 ± 24 | 63 ± 33 | 0.05 |
Total tau, pg/ml | 145 | 348 ± 197 | 445 ± 318 | 0.03 |
MRI—visual scores | ||||
GCA (median, Q1–Q3) | 418 | 0.7 ± 0.7 (1, 0–1) | 1.2 ± 0.8 (1, 1–2) | < .0001 |
MTA, right (median, Q1–Q3) | 398 | 0.6 ± 0.8 (0, 0–1) | 1.4 ± 1.0 (1, 1–2) | < .0001 |
MTA, left (median, Q1–Q3) | 398 | 0.6 ± 0.8 (0, 0–1) | 1.6 ± 1.0 (1, 1–2) | < .0001 |
Fazekas score (median, Q1–Q3) | 420 | 0.8 ± 0.8 (1, 0–1) | 1.1 ± 0.8 (1, 1–2) | 0.009 |